Search Results

• • 12 

    Academic Journals

  • Sort by: sorttype.publication.date.desc Newest sorttype.publication.date.asc Oldest sorttype.relevance Relevance

• A periodic table for cancer

  Author:Richard J EpsteinFrom:Future Oncology (Vol. 11, Issue 5) Peer-Reviewed

  Mar. 20159,314 words Report 2050LAuthor(s): Richard J Epstein [*] aff1 aff2 aff3 KEYWORDS apoptosis; genetic instability; personalized medicine; tumor suppressor genes Scientific progress depends on the discovery of homologies and continuities...

• Intratumoral polymorphonuclear granulocyte is associated with poor prognosis in squamous esophageal cancer by promoting epithelial-mesenchymal transition

  Authors:Pingping Hu, Guanghui Wang, Meixiao Shen, Ping Zhang, Jihong Zhang, Jiajun Du, et al.From:Future Oncology (Vol. 11, Issue 5) Peer-Reviewed

  Mar. 20155,749 words Report 1460LAuthor(s): Pingping Hu aff1 , Guanghui Wang aff2 , Meixiao Shen aff1 , Ping Zhang aff1 , Jihong Zhang aff1 , Jiajun Du [*] aff1 aff2 , Qi Liu [*] aff1 KEYWORDS epithelial-mesenchymal transition; esophageal cancer;...

• Crizotinib in the management of advanced-stage non-small-cell lung cancer

  Authors:Herbert H Loong, Kevin Mok, Linda KS Leung, and Tony SK MokFrom:Future Oncology (Vol. 11, Issue 5) Peer-Reviewed

  Mar. 20157,466 words Report 1680LAuthor(s): Herbert H Loong aff1 aff2 , Kevin Mok aff3 , Linda KS Leung aff1 aff2 , Tony SK Mok [*] aff1 aff2 KEYWORDS acquired resistance; brain metastases; c-Met; crizotinib; EML4-ALK fusion; non-small-cell lung...

• Olaparib: an oral PARP-1 and PARP-2 inhibitor with promising activity in ovarian cancer

  Authors:Camille C Gunderson and Kathleen N MooreFrom:Future Oncology (Vol. 11, Issue 5) Peer-Reviewed

  Mar. 20157,614 words Report 1740LAuthor(s): Camille C Gunderson aff1 , Kathleen N Moore [*] aff1 KEYWORDS BRCA mutation; homologous recombination pathway; PARP inhibitor; olaparib; ovarian cancer Approximately 22,000 cases of ovarian cancer...

• Potential and real 'antineoplastic' and metabolic effect of metformin in diabetic and nondiabetic postmenopausal females

  Authors:Lev M Berstein, Dmitry A Vasilyev, Aglaya G Iyevleva, Marina P Boyarkina, Tatyana E Poroshina, Angela S Khadzhimba, et al.From:Future Oncology (Vol. 11, Issue 5) Peer-Reviewed

  Mar. 20158,306 words Report 1770LAuthor(s): Lev M Berstein [*] aff1 , Dmitry A Vasilyev aff1 , Aglaya G Iyevleva aff2 , Marina P Boyarkina aff1 , Tatyana E Poroshina aff1 , Angela S Khadzhimba aff3 , Evgeny N Imyanitov aff2 KEYWORDS cancer;...

• Future perspectives for mTOR inhibitors in renal cell cancer treatment

  Authors:Anna M Czarnecka, Anna Kornakiewicz, Fei Lian, and Cezary SzczylikFrom:Future Oncology (Vol. 11, Issue 5) Peer-Reviewed

  Mar. 201513,110 words Report 1870LAuthor(s): Anna M Czarnecka [*] aff1 , Anna Kornakiewicz aff1 aff2 , Fei Lian aff3 , Cezary Szczylik aff1 KEYWORDS afinitor; combination treatment; everolimus; mTOR; RAD001; RECORD; renal cell cancer mTOR is a...

• An analysis of the therapeutic benefits of genotyping in pediatric hematopoietic stem cell transplantation

  Authors:Felicity A Wright, Mary Bebawy, and Tracey A O'BrienFrom:Future Oncology (Vol. 11, Issue 5) Peer-Reviewed

  Mar. 201511,691 words Report 2080LAuthor(s): Felicity A Wright aff1 aff2 aff3 , Mary Bebawy aff3 , Tracey A O'Brien [*] aff1 aff4 KEYWORDS pediatrics; pharmacogenetics; polymorphism; stem cell transplantation; transplantation conditioning The...

• Efficacy and safety of ruxolitinib in the treatment of patients with myelofibrosis

  Authors:Cecilia Arana Yi, Constantine S Tam, and Srdan VerstovsekFrom:Future Oncology (Vol. 11, Issue 5) Peer-Reviewed

  Mar. 201511,324 words Report 2320LAuthor(s): Cecilia Arana Yi aff1 , Constantine S Tam aff2 , Srdan Verstovsek [*] aff3 KEYWORDS JAK inhibitor; myelofibrosis; myeloproliferative neoplasm; polycythemia vera; primary myelofibrosis; ruxolitinib;...

• Current and future targeted therapies for non-small-cell lung cancers with aberrant EGF receptors

  Authors:Shanthi Kanthala, Sandeep Pallerla, and Seetharama JoisFrom:Future Oncology (Vol. 11, Issue 5) Peer-Reviewed

  Mar. 201510,734 words Report 1700LAuthor(s): Shanthi Kanthala aff1 , Sandeep Pallerla aff1 , Seetharama Jois [*] aff1 KEYWORDS acquired resistance; afatinib; cetuximab; EGF receptor; gefitinib; neratinib; predictive markers; trastuzumab; tyrosine...

• Clinical trials of stereotactic ablative radiotherapy for prostate cancer: updates and future direction

  Authors:H Bindu Musunuru and Andrew LoblawFrom:Future Oncology (Vol. 11, Issue 5) Peer-Reviewed

  Mar. 20157,608 words Report 1700LAuthor(s): H Bindu Musunuru aff1 aff2 , Andrew Loblaw [*] aff1 aff2 aff3 KEYWORDS image-guided radiotherapy; prostate cancer; quality of life; stereotactic ablative radiotherapy Emerging evidence about the...

• Toward a better management of older patients with acute myeloid leukemia

  Authors:Konstantinos Liapis and Jamie D CavenaghFrom:Future Oncology (Vol. 11, Issue 5) Peer-Reviewed

  Mar. 20152,306 words Report 1880LAuthor(s): Konstantinos Liapis [*] aff1 , Jamie D Cavenagh aff2 KEYWORDS acute myeloid leukemia; azacitidine; older patients The median age at presentation for patients with acute myeloid leukemia (AML) is 67...

• Pancreatic neuroendocrine tumors: a review

  Authors:Kate Young, Ridhima Iyer, Daniel Morganstein, Ian Chau, David Cunningham, and Naureen StarlingFrom:Future Oncology (Vol. 11, Issue 5) Peer-Reviewed

  Mar. 20158,122 words Report 1820LAuthor(s): Kate Young aff1 , Ridhima Iyer aff1 , Daniel Morganstein aff1 , Ian Chau aff1 , David Cunningham aff1 , Naureen Starling [*] aff1 KEYWORDS DOTATATE; everolimus; NETs; neuroendocrine tumors; pancreatic...